MARLBOROUGH, Mass. — A laser typically used to smooth wrinkles may have a second, far more consequential job: rewriting the skin’s biological clock. Peer-reviewed research published today in Scientific Reports shows that Candela’s Nordlys 1940 nm non-ablative fractional laser does not just resurface skin. It alters DNA methylation patterns — the chemical tags on DNA that change as people age and as skin is exposed to the sun.
The study provides the first in vivo human evidence that a non-ablative fractional laser can reverse the skin’s epigenetic signature of aging. The implications for regulation and medical policy are immediate.
If a cosmetic laser can modify the epigenetic marks linked to skin cancer, then the device’s approved uses may need to be reconsidered. Currently, the Nordlys system is marketed for aesthetic treatments. The study’s authors found a direct molecular link to skin cancer biology.
That shifts the conversation from vanity to prevention. The paper dropped at 9:07 a.m. Eastern time.
Candela Corporation, based here, announced the results. The company manufactures the Nordlys system. The journal is part of the Nature Portfolio, a respected scientific publishing group.
Peer review lends credibility to the claim. Scientists have long known that DNA methylation patterns change as skin ages. These epigenetic modifications influence gene expression and cellular function.
The new evidence suggests the 1940 nm laser can reverse some of those age-related changes. That is a fundamental shift in understanding how laser treatments work at the cellular level.
For regulators at the U.S. Food and Drug Administration, the study raises questions. The device was cleared for cosmetic use — removing wrinkles, improving texture. If it also changes methylation patterns tied to cancer, does that make it a medical treatment?
Should the labeling change? Should a prescription be required?
Those are not academic questions. The FDA classifies devices based on their intended use. If the manufacturer begins marketing the Nordlys as a cancer-prevention tool, the agency could require a new premarket approval application.
That process is expensive and time-consuming. It also opens the door to broader insurance coverage. Currently, cosmetic laser treatments are not covered by most health plans.
Patients pay out of pocket. If the laser gains a medical indication — for reducing skin cancer risk — that calculus changes.
Private insurers and Medicare would face pressure to reimburse the procedure. The cost-benefit analysis would hinge on how much the treatment reduces actual cancer incidence, not just epigenetic markers. The study does not answer that question.
It shows a molecular change. It does not prove the laser prevents tumors.
Researchers will need to run long-term clinical trials to connect the epigenetic remodeling to lower cancer rates. Those trials take years. But the regulatory clock starts ticking now.
The FDA has a process for handling new evidence about already-cleared devices. The agency can issue a safety communication, request additional data, or reclassify the device. It can also do nothing, waiting for the manufacturer to seek a new indication.
Candela has not announced plans to pursue a cancer-prevention label. The company’s press release focused on the study’s publication.
But the science is public. Other researchers can replicate it. Dermatologists can read the paper and decide whether to discuss the findings with patients.
That creates a policy gray zone. A doctor could legally use a cleared device off-label for any purpose.
If a dermatologist believes the Nordlys laser reduces skin cancer risk, the doctor can offer it. The patient pays. The insurer does not.
The FDA does not stop it, as long as the manufacturer does not promote the off-label use. The study lands in that space. It provides evidence.
It does not provide a regulatory mandate. What it does is force a conversation — inside the FDA, inside Candela, inside dermatology clinics — about what a laser that rewrites methylation is actually for.
